icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
VND8T5Mfhum1BnyX
Listen
